MOS
CRSP icon

MGO One Seven’s CRISPR Therapeutics CRSP Stock Holding History

MGO One Seven’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,936
Closed -$313K – 607
2021
Q2 		$313K Sell
1,936
-494
-20% -$60.1K 0.04% 436
2021
Q1 		$296K Buy
2,430
+350
+17% +$52.8K 0.05% 417
2020
Q4 		$318K Buy
+2,080
New +$246K 0.07% 350
2019
Q1 		– Sell
-2,000
Closed -$57K – 650
2018
Q4 		$57K Buy
+2,000
New +$69.5K 0.02% 595
2018
Q1 		$91K Hold
2,000
– – 0.04% 463
2017
Q4 		$47K Buy
+2,000
New +$38K 0.02% 625

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MGO One Seven's CRSP Position: Q3 2021 in Review

MGO One Seven sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 1,936 shares — an estimated $313K sold.

MGO One Seven first reported a position in CRSP in Q4 2017 and held it in 6 quarters. The position peaked at $318K in Q4 2020. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • MGO One Seven reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • MGO One Seven sold 1,936 CRISPR Therapeutics shares in Q3 2021, an estimated $313K.
  • MGO One Seven first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 6 quarters.
  • MGO One Seven's CRISPR Therapeutics position peaked at $318K in Q4 2020.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on MGO One Seven's 13F filing for Q3 2021, filed 9 Nov 2021.